Haf and haf.

Two-years of follow-up after the first big hafnium-oxide trial reveals almost double to rate of grade 3+ toxicities in the arm not receiving the novel radiosensitizer, and there was no detriment to quality of life pertaining to late fibrosis or joint stiffness. | Bonvalot, Int J Radiat Oncol Biol Phys 2022


Popular Posts